Medicare Part D plans "overcharged" $4.4B

9 February 2009

The Office of Inspector General, part of the US Department of Health and Human Services, has accused the Centers for Medicare and Medicaid  Services (CMS) of failing to perform required audits of payments under  the Part D prescription drug benefit for seniors. As a result of this  alleged lapse in 2006, an estimated $4.4 billion was overcharged by  about 80% of plan providers.

The damning report follows another by the Government Accountability  Office, which noted that profits for insurers were $1.3 billion above  expectations, although this was explained by deeper than expected  discounts for prescription medicines negotiated by prescription benefit  managers (Marketletter January 5 & 12).

The CMS admitted that it had not conducted most of the 165 audits it was  supposed to complete for the 2006 period. The GAO said that in April  2007 only seven had been carried out, although the CMS now states that  103 have been either completed or are underway.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK







Today's issue

Company Spotlight